Impact of the insertion of the clinical pharmacist in the Allogeneic Hematopoietic Stem Cells Transplantation team
Journal of Oncology Pharmacy Practice · 2023-03 · 29 (2) · 375-385
DOI: 10.1177/10781552211073797 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology Pharmacy Practice, online erschienen am 17.01.2022. Verfasst von Maria Olívia Barboza Zanetti und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Brazilian National Council for Scientific and Technological Development.
Abstract (Originalsprache)
Introduction
Allogeneic Hematopoietic Stem Cells Transplantation (allo-HSCT) is capable of curing patients with neoplastic or non-neoplastic hematologic disorders or of prolonging their survival. This study assessed if the insertion of the clinical pharmacist in the allo-HSCT team modified the outcomes: transplantation-related mortality, grafting failure, incidence of Graft versus Host Disease, hospitalization time, time for grafting, number of readmissions, number of drug-related problems (DRPs), adherence and knowledge about pharmacotherapy.
Methods
Interventional study with historical control carried out in an allo-HSCT unit, in which the intervention group (IG) included 33 individuals who received pharmacotherapy follow-up. Control Group (CG) consisted of 28 individuals.
Results
A total of 250 DRPs were identified, 59 team's doubts were clarified, and 309 interventions were conducted in the IG. The DRPs mainly arose from safety (51.60%) and effectiveness (38.40%) problems. A mean of 9.36 (SD = 6.97) interventions per patient was obtained, mainly including dose reductions (19.09%), adjustments in administration time (18.12%), educational activities (15.21%) and drug removal (10.68%). Clinical significance of the interventions was considered high (75.7% extremely significant, very significant or significant), as well as their acceptability (89.7% accepted). Each patient attended a mean of 4.68 pharmaceutical consultations (SD = 1.91) after hospital discharge, presenting increase in knowledge (p = 0.0001) and in adherence (p = 0.0115). There was no evidence of differences between the groups in the other outcomes analyzed.
Conclusions
The pharmacotherapy follow-up allowed detecting several DRPs and performing interventions of high clinical relevance and acceptability, in addition to improving adherence and individualizing the pharmacotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
- Ribeirao Preto Medical School, University of Sao Paulo, Ribeirao Preto, Sao Paulo, Brazil.
ORCID-Profile: Maria Olívia Barboza Zanetti, João Paulo Vilela Rodrigues
Förderung
- Brazilian National Council for Scientific and Technological Development
Zitieren
APA
Zanetti, M. O. B., Rodrigues, J. P. V., Varallo, F. R., Cunha, R. L. G., Simões, B. P., & Pereira, L. R. L. (2023). Impact of the insertion of the clinical pharmacist in the Allogeneic Hematopoietic Stem Cells Transplantation team. Journal of Oncology Pharmacy Practice, 29(2), 375-385. https://doi.org/10.1177/10781552211073797
Vancouver
Zanetti MOB, Rodrigues JPV, Varallo FR, Cunha RLG, Simões BP, Pereira LRL. Impact of the insertion of the clinical pharmacist in the Allogeneic Hematopoietic Stem Cells Transplantation team. Journal of Oncology Pharmacy Practice. 2023;29(2):375-385. doi:10.1177/10781552211073797
BibTeX
@article{Zanetti2023,
author = {Zanetti, Maria Olívia Barboza and Rodrigues, João Paulo Vilela and Varallo, Fabiana Rossi and Cunha, Renato Luiz Guerrino and Simões, Belinda Pinto and Pereira, Leonardo Régis Leira},
title = {Impact of the insertion of the clinical pharmacist in the Allogeneic Hematopoietic Stem Cells Transplantation team},
journal = {Journal of Oncology Pharmacy Practice},
year = {2023},
volume = {29},
number = {2},
pages = {375--385},
doi = {10.1177/10781552211073797}
}
EUVIMED